Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.58 |
| ▸ | GPR4 | P46093 | 2/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3320226 | 0.86 | CTSK (0.47) | CTSKGPR4FGFR4GPR119CTSS | |
| SCHEMBL3316066 | 0.81 | GPR4 (0.37) | CTSKGPR4 | |
| SCHEMBL8270653 | 0.80 | CTSK (0.67) | CTSKGPR4FGFR4GPR119OPRM1 | |
| SCHEMBL5792733 | 0.80 | CTSK (0.52) | CTSKGPR4FGFR4GPR119OPRM1 | |
| SCHEMBL5791035 | 0.76 | CTSK (0.45) | CTSKGPR4FGFR4GPR119 | |
| SCHEMBL8268758 | 0.75 | CTSK (0.60) | CTSKGPR4FGFR4GPR119CTSS | |
| SCHEMBL5794380 | 0.74 | FGFR4 (0.41) | CTSKGPR4FGFR4GPR119CTSS | |
| SCHEMBL3315262 | 0.73 | CTSK (0.61) | CTSKGPR4FGFR4 | |
| SCHEMBL6219623 | 0.73 | CTSK (0.71) | CTSKGPR4FGFR4 | |
| SCHEMBL5793805 | 0.73 | CTSK (0.52) | CTSKGPR4FGFR4GPR119CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED | 2010-04-29 | — | — | US | disclosed |
| EP-2118106-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited (GB) | 2009-11-18 | — | — | EP | disclosed |
| EP-2028182-A1 | Cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2009-02-25 | — | — | EP | disclosed |
| EP-1972630-A1 | Purines as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2008-09-24 | — | — | EP | disclosed |
| WO-2008107368-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-09-12 | — | — | WO | disclosed |
| WO-2006027211-A1 | 2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105652-A1 | PURINES AS CYSTEINE PROTEASE INHIBITORS | CPN1, SERPINB1, PNP | CTSK 135/4885GPR4 4360/4885FGFR4 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.